Teleflex Incorporated Stock News

SAN FRANCISCO , March 11, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Central Venous Catheters (CVCs) - Global Market Trajectory & Analytics" . The report presents fresh perspectives on opportunities and challenges in a significantly transformed post COVID-19 marketplace. FACTS AT A GLANCE What''s New for 2022? Global competitiveness and key competitor percentage market shares Market presence across multiple geographies - Strong/Active/Niche/Trivial Online interactive peer-to-peer collaborative bespoke updates Access to our digital archives and MarketGlass Research Platform Complimentary updates for one year Edition: 7; Released: February 2022 Executive Pool: 4019 Companies: 61 - Players covered include Amecath; AngioDynamics Inc.; B. Braun Melsungen AG; Bactiguard AB; Becton, Dickinson and Company; COOK MEDICAL LLC; Edwards Lifesciences Corporation; Guangdong Baihe Medical Technology Co., Ltd; ICU Medical, Inc.; Insung Medical Co.

Teleflex (TFX) continues to face supply-chain challenges and freight logistic delays.

WAYNE, Pa., March 09, 2022 (GLOBE NEWSWIRE) -- Thomas Powell, Executive Vice President and Chief Financial Officer, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the KeyBanc Life Science

Teleflex Incorporated found using ticker (TFX) have now 9 analysts in total covering the stock. The consensus rating is ''Buy''. The range between the high target price and low target price is between 455 and 325 with a mean TP of 408.56. Given that the stocks previous close was at 343.32 this is indicating there is a potential upside of 19.0%. The 50 day moving average now sits at 323.81 and the 200 moving average now moves to 361.13. The company has a market capitalisation of $16,395m. Find out more information at: https://www.teleflex.com [stock_market_widget type="chart" template="basic" color="green" assets=TFX" range="6mo" interval="1d" axes="true" cursor="true" api="yf"] The potential market cap would be $19,510m based on the market concensus. Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. It provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.

WAYNE, Pa., March 02, 2022 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the 43 rd Annual Raymond James Institutional Investors Conference at the JW Marriott Orlando Grande Lakes, Orlando, FL, on Tuesday, March 8, 2022, at 9:15 a.m. (ET).

WAYNE, Pa., March 02, 2022 (GLOBE NEWSWIRE) -- Liam Kelly, Chairman, President and CEO, Teleflex Incorporated (NYSE: TFX), is scheduled to speak at the 43rd Annual Raymond James Institutional Investor

Strong segmental performance in the domestic and international markets is driving Teleflex's (TFX) fourth-quarter top line.

Endoscopy Equipment Market Research Report Gives in Detailed Analysis of Industry Segments, Opportunities, Growth and Size That Will Help Your Business Grow. Northbrook, IL -- ( SBWIRE ) -- 02/24/2022 -- This report aims to provide detailed insights into the global endoscopy equipment market . It provides valuable information on the type, procedure, application, and region in the market. Furthermore, the information for these segments, by region, is also presented in this report. Leading players in the market are profiled to study their product offerings and understand the strategies undertaken by them to be competitive in this market. Expected Revenue Growth: The global endoscopy equipment market is projected to reach USD 39.3 billion by 2026 from USD 27.3 billion in 2021, at a CAGR of 7.5%. Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=689 Key Factors Driving Market Growth: The key factors driving the growth of endoscopy equipment market include favorable government initiatives, rising number of hospitals and growing hospital investments in endoscopy facilities, technological advancements, and rising prevalence of diseases that require endoscopy.

Teleflex Incorporated (NYSE: TFX ) reported Q4 FY21 revenues of $761.9 million , up 7.1% Y/Y, up 7.9% on a constant currency basis, beating the consensus of $748.63 million. The revenue growth was attributable to higher sales from Anesthesia and … Full story available on Benzinga.com

Teleflex Inc. (TFX) CEO Liam Kelly on Q4 2021 Results - Earnings Call Transcript

Teleflex (TFX) declares $0.34/share quarterly dividend, in line with previous.Forward yield 0.42%Payable March 15; for shareholders of record March 7; ex-div March 4.See TFX…

Teleflex press release (TFX): Q4 Non-GAAP EPS of $3.60 beats by $0.07.Revenue of $761.91M (+7.1% Y/Y) beats by $12.31M.For FY2022, the company expects GAAP revenue growth of 2.3%…

Teleflex (TFX) delivered earnings and revenue surprises of 1.98% and 1.87%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?